How to Dose Retatrutide

Retatrutide is dosed once weekly by subcutaneous injection. The Body Pharm pen protocol is a simple 4-week ladder: 2 mg for four weeks, 4 mg for four weeks, then 8 mg for four weeks, with 12 mg once weekly as the maximum. Hold each step for the full four weeks before going up.

The finer 2 → 4 → 6 → 9 → 12 mg ladder that appears in the TRIUMPH Phase 3 trial design is a clinical-trial reference, not the product dosing instruction — it is described later in this guide for context only [1][6].

Retatrutide remains an unlicensed investigational peptide in the UK as of 2026; nothing below constitutes medical advice.

Key Takeaways

• Start at 2 mg weekly for four weeks; advance only if all four tolerability criteria are met (nausea resolves within 48 hours, zero vomiting in 14 days, appetite suppression present but intake above ~1,200 kcal/day, injection-site reactions fully resolved).
• Hold each dose tier for the full four weeks regardless of tolerability; advancing early is the single most common cause of gastrointestinal intolerance.
• The 8 mg dose is the efficacy-tolerability sweet spot; 12 mg produces higher weight loss (24.2% at 48 weeks) but with substantially greater nausea and constipation burden.
• Retatrutide's triple-receptor mechanism (GIP/GLP-1/glucagon) demands tighter titration discipline than semaglutide or tirzepatide because glucagon activity widens the side-effect window at every step.
• Store pens at 2–8 °C, protected from light; never freeze. Warm to room temperature 20–30 minutes before injection.

What Is Retatrutide and How Does It Work?

Retatrutide is a single-molecule triple receptor agonist that activates the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon receptors. Eli Lilly developed it and first reported it in the Phase 2 obesity trial by Jastreboff et al. in the New England Journal of Medicine, June 2023 [5][2].

The glucagon arm separates it pharmacologically from semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1). Glucagon receptor activity drives hepatic lipid mobilisation and a modest thermogenic component on top of the appetite and gastric-emptying effects driven by the incretin arms [3].

For dosing, that third receptor matters in two ways. The efficacy ceiling is higher (approximately 24.2% mean weight loss at 48 weeks on the 12 mg arm) [5]. The titration window must also accommodate glucagon-linked effects, heart rate drift, hepatic flux, alongside the familiar incretin gastrointestinal profile, so step-ups are spaced more conservatively than a tirzepatide ladder [3]. Some researchers worry that the additional receptor complexity will prove harder to tolerate than dual agonists; the Phase 2 data suggest that a disciplined four-week hold at each tier substantially mitigates this risk.

See the retatrutide vs semaglutide vs tirzepatide comparison for the mechanism contrast, and how to dose tirzepatide for the dual-agonist parallel.

As of 2026, retatrutide holds no MHRA (Medicines and Healthcare products Regulatory Agency) marketing authorisation and is classed as an unlicensed investigational peptide in the UK [1][6].

Retatrutide Dosing Schedule at a Glance (2026)

The canonical research titration is a four-step ladder: an optional 0.5 mg microdose for sensitivity screening, a 2 mg standard start, a 4 mg step, and 8 mg maintenance, each held for four weeks before advancing [3][5]. The 8 mg dose is the efficacy-tolerability sweet spot identified in Jastreboff et al., NEJM 2023, which reported approximately 17.5% mean body weight reduction at 24 weeks in the 8 mg cohort [2][5].

Hold each step for the full four weeks regardless of how well it is tolerated. Advancing early is the single most common cause of gastrointestinal intolerance in research runs [3][6].

The 12 mg row is included for completeness because the Phase 2 trial escalated through 1 mg, 2 mg, 4 mg, 8 mg and 12 mg arms, with the 12 mg cohort reaching approximately 24.2% mean weight loss at 48 weeks at the cost of a heavier nausea and constipation burden [2][5]. Most researchers stop at 8 mg.

For the rationale behind this ladder over a dual-agonist comparator, see retatrutide vs semaglutide vs tirzepatide; for the parallel GIP/GLP-1 schedule, see how to dose tirzepatide.

Why Start at 2 mg (or 0.5 mg)?

Rapid escalation to therapeutic levels triggers vagally mediated nausea severe enough to terminate a research run. GLP-1 receptor agonism in the area postrema and nucleus tractus solitarius drives the emetic response. Starting low gives central receptors time to downregulate before exposure climbs [6][1].

Phase 2 data make the case quantitatively. Jastreboff et al. (NEJM, 2023) reported that gastrointestinal adverse events were the dominant tolerability signal across all retatrutide arms and scaled steeply with the size of each escalation step [2][5]. Slower step-up protocols (starting at 2 mg rather than jumping straight to 4 mg) materially reduced gastrointestinal burden during the ramp [6][1]. Each 4-week hold at 2 mg, 4 mg and 8 mg keeps the receptor population ahead of the dose. Researchers concerned that a slow start will delay efficacy should note that the 8 mg sweet spot is reached by week 9 regardless, and the gastrointestinal tolerance built in weeks 1–8 translates to better adherence and longer-term retention.

When to consider the 0.5 mg microdose

The 0.5 mg pre-ramp is not in the Jastreboff protocol. It is a convention borrowed from semaglutide and tirzepatide practice for researchers with a documented history of gastrointestinal sensitivity to incretin agonists, particularly anyone who tolerated 0.25 mg semaglutide poorly or who needed antiemetic cover during a prior tirzepatide titration [3][4]. The logic is identical: a sub-therapeutic priming dose lets the gut and central receptors acclimatise before the standard ladder begins.

For comparator context, see retatrutide vs semaglutide vs tirzepatide; the parallel ramp logic is mapped out in how to dose tirzepatide.

The Four-Week Hold Rule: When to Advance

The next dose tier is reached only after four consecutive weeks at the current dose with all four tolerability criteria met; otherwise the dose is held or stepped back. The four-week minimum is the receptor-adaptation window inherited directly from the Jastreboff et al. 2023 Phase 2 titration arms [5], not an arbitrary calendar convention.

The checklist below is Body Pharm's protocol synthesis, derived from but not validated by the Phase 2 schedule. Treat it as expert-opinion scaffolding rather than trial-confirmed criteria.

If all four criteria are clean at week 4, the protocol advances. If any one fails, the dose is held for a further two weeks at the same level and reassessed at week 6. If the same criterion still fails at week 6, the protocol drops back one tier (for example, 4 mg to 2 mg) for four weeks before the step-up is attempted again. Repeated failure at the same threshold means the receptor population has not caught up with the agonist load; forcing the ladder produces exactly the gastrointestinal burden the slow-titration arm was designed to avoid [5][6].

The four-week minimum is not a four-week maximum

Several 2024–2025 practice-based frameworks describe researchers holding at 4 mg for 8–12 weeks before advancing to 8 mg. The rationale is that extended mid-ladder dwell time improves long-term tolerability and reduces dropout at the 8 to 12 mg transition [1][3]. This is expert opinion, not trial data [unverified], but the pharmacological logic is sound. The 4 to 8 mg jump is where gastrointestinal events sharpened in Phase 2 [6]. A longer 4 mg plateau gives central and peripheral receptors more time to downregulate before the next step.

For step-spacing parallels in a dual agonist, the how to dose tirzepatide guide uses the same hold-versus-advance logic against tirzepatide's narrower side-effect window.

Subcutaneous Injection Protocol: Step-by-Step

The Body Pharm multi-dose pen delivers retatrutide subcutaneously without reconstitution. Reported technique dials the dose, injects at 90° into the abdomen or thigh over 5–10 seconds, and rotates sites within a structured grid. The procedure below assumes a 32 mg or 64 mg pen stored at 2–8 °C and protected from light.

Site rotation

The same 2 cm zone is not reused within seven days in reported protocols. A four-quadrant grid on each abdominal flank (eight zones total), cycled clockwise, is a commonly described pattern. This prevents the lipohypertrophy and erratic absorption that plague insulin users running tight rotation patterns. The same principle from NHS subcutaneous injection guidance applies to insulin technique.

Pen format vs vial-and-syringe

The multi-dose pen eliminates reconstitution with bacteriostatic water, syringe-volume calculation, and the dead-space losses that accompany lyophilised vials. You set the dose directly on the dial in milligrams — the pen dials every step of the ladder (2, 4, 8 and up to the 12 mg maximum) — so there is no click-counting or volume maths. The 32 mg and 64 mg pens both work this way; they do NOT deliver the same amount per click (the per-click amount differs), but that does not matter because you read the mg off the dial. The 64 mg pen simply holds more, so it lasts longer at any given maintenance dose. For researchers comparing peptide delivery formats across the cluster, the retatrutide vs semaglutide vs tirzepatide guide covers why pen-format dosing accuracy matters more for triple agonists than for narrower-window GLP-1 monotherapies.

No validated in-use stability data are published for these pens [unverified]. Discard any pen if the solution clouds, discolours, or shows particulates.

Managing Side Effects at Each Dose Tier

Side-effect intensity tracks the titration ladder almost linearly: mild and self-limiting at 2 mg, transient but noticeable at 4 mg, and clinically meaningful at 8 mg and above. Response is organised by tier in reported protocols, rather than reacting to symptoms as they appear.

2 mg tier

Expect mild appetite suppression within 48 hours of the first injection. In a minority of cases, transient nausea on injection day resolves inside 24 hours. No symptomatic intervention is warranted at this tier. If nausea persists beyond 48 hours at 2 mg, hold the step rather than advancing, a poor 2 mg run predicts a worse 4 mg run.

4 mg tier

Nausea commonly persists 24–48 hours post-injection during the first one or two doses at 4 mg [1]. The pragmatic convention from the GLP-1 research community is to inject in the evening so peak nausea coincides with sleep. This is operator experience, not trial-derived. Maintain fluid intake at a minimum of 2 litres per day, as reduced appetite frequently drags water intake down with it.

8 mg tier

Nausea and fatigue cluster in weeks 1–2 at 8 mg. Constipation becomes the dominant complaint thereafter. Jastreboff et al. (NEJM, 2023) reported constipation in roughly a quarter of participants in the higher-dose arms, though precise per-cohort breakdowns are not published in open summaries [unverified]. Pre-empt with 25–30 g daily dietary fibre and sustained fluid intake before symptoms appear. Reactive management at this tier is consistently slower than prophylaxis. If constipation persists beyond seven days despite fibre and fluids, hold the next step.

12 mg tier

Gastrointestinal burden is highest here and was the principal tolerability ceiling in the 2023 Phase 2 data [1][2]. Many researchers maintain at 8 mg precisely to avoid this. Advancing beyond 8 mg is reported to bring a 2–3 week re-acclimation window.

Across all tiers

Injection-site redness or mild bruising is normal and resolves within 48 hours. Persistent subcutaneous nodules indicate poor rotation, so the site map should be reviewed before attributing the effect to the compound. Hypoglycaemia is not a primary risk because retatrutide's incretin action is glucose-dependent. Researchers stacking with insulin sensitisers, sulfonylureas, or other incretins should account for additive effects. For comparative side-effect profiles against the dual agonist, the how to dose tirzepatide guide breaks down where the two diverge most sharply at the 8 mg-equivalent tier.

Retatrutide vs Semaglutide vs Tirzepatide: Dosing Differences

Retatrutide demands tighter titration discipline than its dual- and mono-agonist comparators because glucagon receptor agonism widens the side-effect window at every step. The table below maps the three ladders side by side; all use 4-week steps as the default escalation cadence.

A researcher accustomed to semaglutide's narrow dose range will underestimate the gastrointestinal burden of stepping from 8 to 12 mg retatrutide. The 2023 Phase 2 data showed the steepest tolerability drop-off at this transition [5][2]. Tirzepatide sits between the two for side-effect intensity but lacks the glucagon-driven hepatic and energy-expenditure effects that make retatrutide attractive in the first place. For the full mechanistic and outcome comparison, see retatrutide vs semaglutide vs tirzepatide; for the dual-agonist protocol in isolation, the how to dose tirzepatide guide runs the same ladder format.

Pen Storage, Handling, and Shelf Life

Store retatrutide pens refrigerated at 2–8 °C, protected from light in their original packaging, and never frozen. Freezing destabilises the peptide irreversibly. Ambient light exposure accelerates degradation even when the cartridge looks intact.

No validated in-use stability data have been published for unlicensed retail retatrutide pens as of early 2026. Treat any vendor-stated post-puncture window as provisional and refer to the specific product page (Retatrutide 32 and Retatrutide 64) for the figure the supplier is willing to stand behind. By way of analogous reference, MHRA-licensed GLP-1 pens such as Ozempic specify 2–8 °C until first use and a bounded room-temperature in-use window after that. Retatrutide should be handled at least as conservatively.

Operational checks before every injection:

• Inspect the cartridge against a white background. Discard if the solution is cloudy, discoloured, or shows visible particulates.
• Remove the pen from the fridge 20–30 minutes before dosing so the solution reaches roughly 20–25 °C. Cold injection stings and can affect dose-delivery consistency on spring-driven pens.
• For travel, use an insulated cool bag with a gel pack separated from the pen by a cloth layer. Direct ice contact risks localised freezing of the cartridge.

If a pen has been left at room temperature longer than the supplier's stated in-use window, treat it as compromised rather than salvageable.

Frequently Asked Questions

Five questions surface repeatedly in research forums and correspondence. The answers below are anchored to the 2023 Phase 2 dataset and the practical pen-volume maths already covered.

Can the weekly dose be split into two injections?

No. Retatrutide is a once-weekly subcutaneous peptide with a multi-day half-life sufficient to maintain steady plasma exposure across a 7-day interval [2]. Splitting an 8 mg dose into two 4 mg injections lowers peak concentration without meaningfully reducing the gastrointestinal side-effect burden. Nausea tracks cumulative weekly exposure rather than peak. The Phase 2 protocol used single weekly injections throughout [5].

What happens if a scheduled dose is missed?

The missed dose is injected as soon as it is remembered, provided fewer than 4 days have elapsed since the scheduled day. If the gap is longer, that week's dose is skipped entirely and dosing resumes on the next scheduled day at the same dose. Double-dosing to compensate is not recommended, as the resulting peak exposure reliably triggers nausea and vomiting at maintenance doses of 8 mg and above [1].

Is 8 mg the maximum dose, or is escalation to 12 mg warranted?

8 mg is the practical maintenance ceiling for most research runs. 12 mg was the maximum tested in the Jastreboff et al. 2023 Phase 2 obesity trial and produced approximately 24% mean weight loss at 48 weeks, but with a clearly higher gastrointestinal adverse-event burden than 8 mg [5][2]. The TRIUMPH Phase 3 programme retains 12 mg as the top arm via a 2→4→6→9→12 mg ladder [1]. For comparator context, see retatrutide vs semaglutide vs tirzepatide.

Can retatrutide be stacked with other peptides?

The 2023 Phase 2 dataset and all 2024–2025 practice-based frameworks address retatrutide as monotherapy only. No peer-reviewed work covers co-administration with semaglutide, tirzepatide, or other incretin agonists [2][3]. Combining incretin agonists produces additive nausea, delayed gastric emptying, and constipation. Anyone running a parallel tirzepatide protocol should consult how to dose tirzepatide and treat overlap as contraindicated.

How many weeks does each pen last at maintenance dose?

A 32 mg pen delivers four weeks of 8 mg/week dosing. A 64 mg pen delivers eight weeks at the same maintenance dose. At 4 mg/week (early titration), the 32 mg pen extends to eight weeks and the 64 mg to sixteen, though in-use stability constraints will usually force discard before the cartridge is empty.

Research Disclaimer and Legal Status in the UK

Retatrutide is not approved by the MHRA for human use as of 2026 and does not appear on the register of authorised human medicines [6]. It remains an investigational triple agonist whose primary evidence base is the Jastreboff et al. Phase 2 obesity trial (NEJM, 2023) [2][5]. The TRIUMPH Phase 3 programme is still pre-publication [1].

All Body Pharm retatrutide pens are sold strictly for research and analytical purposes only and are not intended for human consumption. This guide summarises dosing reported in published literature and does not constitute medical advice. Researchers should consult the primary NEJM 2023 paper and relevant institutional ethics frameworks; for comparator context see retatrutide vs semaglutide vs tirzepatide and how to dose tirzepatide.

Next Steps

Reviewing the Phase 2 protocol in Jastreboff et al. (NEJM, 2023) before beginning titration is recommended. A four-week injection log with columns for date, time, site, dose, pen lot and tolerability notes is standard practice. Researchers with prior experience with semaglutide or tirzepatide can consult the retatrutide vs semaglutide vs tirzepatide comparison to understand where the triple agonist diverges most sharply. Starting at 2 mg and committing to the full four-week hold at each tier is the reported protocol; early advancement is the most common cause of dropout due to gastrointestinal intolerance.

References

1. TRIUMPH Phase 3 programme (retatrutide), pre-publication clinical trial programme — no journal paper available as of 2026.
2. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
3. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
4. Semaglutide/tirzepatide microdosing pre-ramp — practice-based convention borrowed from incretin titration experience; not trial-validated.
5. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
6. UK regulatory status — retatrutide is unlicensed/investigational and not on the MHRA register of authorised human medicines as of 2026.